Short-term efficacy and influencing factors of conventional chemotherapy combined with irinotecan in patients with advanced gastric cancer

Table 1 Comparison of clinical general data between the observation and control groups

Clinical general data	Observation group (n = 40)	Control group (n = 40)	t/χ2 value	P value
Gender, n (%)			0.050	0.823
Male	22 (55.00)	21 (52.50)
Female	18 (45.00)	19 (47.50)
Age (yr)	62.21 ± 7.78	61.10 ± 8.43	0.612	0.542
Body mass index (kg/m2)	22.40 ± 2.05	22.16 ± 1.95	0.536	0.593
KPS score (points)	72.21 ± 5.54	71.19 ± 5.80	0.804	0.424
TNM stage, n (%)			0.238	0.626
IIIb	27 (67.50)	29 (72.50)
IV	13 (32.50)	11 (27.50)

KPS: Karnofsky Performance Scale; TNM: Tumor node metastasis.

Table 2 Comparison of short-term efficacy between two groups, n (%)

Group	Cases	CR	PR	SD	PD	Z value	P value
Observation group	40	2 (5.00)	21 (52.50)	12 (30.00)	5 (12.50)	-2.799	0.005
Control group	40	0 (0.00)	13 (32.50)	12 (30.00)	15 (37.50)

CR: Complete remission; PR: Partial remission; SD: Stable disease; PD: Progressive disease.

Table 3 Comparison of clinical data of effective and ineffective patients in observation group

Clinical data	Chemotherapy effective (n = 23)	Chemotherapy ineffective (n = 17)	t/χ2 value	P value
Gender, n (%)			0.051	0.822
Male	13 (56.62)	9 (52.94)
Female	10 (43.48)	8 (47.06)
Age (yr)	60.60 ± 5.56	65.12 ± 5.71	-3.587	0.001
Body mass index (kg/m2)	22.14 ± 2.03	22.75 ± 2.12	-1.314	0.193
KPS score (points)	75.54 ± 4.32	67.70 ± 3.83	8.589	0.000
TNM stages, n (%)			5.631	0.018
IIIb	19 (82.61)	8 (47.06)
IV	4 (17.39)	9 (52.94)

KPS: Karnofsky Performance Scale; TNM: Tumor node metastasis.

Table 4 Comparison of tumor markers before and after treatment in two groups

Index	Observation group (n = 40)	Control group (n = 40)	t value	P value
CA199 (mg/L)
Before treatment	110.43 ± 21.32	108.28 ± 19.82	0.467	0.642
1 wk after treatment	71.22 ± 17.28a	88.01 ± 13.34a	-4.864	0.000
1 mo after treatment	44.49 ± 15.52a,d	69.32 ± 12.10a,d	-7.980	0.000
CEA (ng/L)
Before treatment	46.69 ± 7.80	47.05 ± 8.00	-0.204	0.839
1 wk after treatment	32.21 ± 6.65a	40.40 ± 7.71a	-5.087	0.000
1 mo after treatment	11.38 ± 3.03a,d	28.83 ± 6.62a,d	-15.159	0.000
NSE (mg/L)
Before treatment	22.23 ± 3.54	22.40 ± 3.70	-0.210	0.834
1 wk after treatment	17.39 ± 3.11a	19.40 ± 2.83a	-3.023	0.003
1 mo after treatment	12.23 ± 2.29a,d	17.73 ± 2.69a,d	-9.847	0.000
EGFR (mg/L)
Before treatment	22.43 ± 5.54	22.15 ± 4.48	0.249	0.804
1 wk after treatment	16.67 ± 2.11a	19.22 ± 2.17a	-5.328	0.000
1 mo after treatment	6.60 ± 1.92a,d	11.11 ± 2.01a,d	-10.262	0.000

^aP < 0.05 vs before treatment.

^dP < 0.05 vs 1 wk after treatment.

CA199: Carbohydrate antigen 199; CEA: Carcinoembryonic antigen; NSE: Neuron-specific enolase; EGFR: Epidermal growth factor receptor.

Table 5 Comparison of SF-36 scale scores before and after treatment in two groups

Index	Observation group (n = 40)	Control group (n = 40)	t value	P value
Physiological function
Before treatment	52.34 ± 6.89	54.11 ± 7.04	-1.136	0.259
3 mo after treatment	65.12 ± 8.14a	60.32 ± 8.04a	2.653	0.010
Role-physical
Before treatment	60.43 ± 7.92	59.90 ± 8.04	0.297	0.767
3 mo after treatment	64.54 ± 8.09a	63.93 ± 7.90a	0.341	0.734
Bodily pain
Before treatment	31.88 ± 7.78	32.01 ± 8.09	-0.073	0.942
3 mo after treatment	38.00 ± 8.12a	38.70 ± 9.17a	-0.361	0.719
General health
Before treatment	58.56 ± 9.15	57.74 ± 9.03	0.403	0.688
3 mo after treatment	66.43 ± 7.12a	65.80 ± 9.22a	0.342	0.733
Energy
Before treatment	40.32 ± 7.22	38.75 ± 8.11	0.914	0.363
3 mo after treatment	54.76 ± 6.70a	47.21 ± 7.14a	4.877	0.000
Social function
Before treatment	51.21 ± 6.98	51.33 ± 7.54	-0.074	0.941
3 mo after treatment	61.89 ± 6.45a	60.40 ± 7.16a	0.978	0.331
Emotional function
Before treatment	31.65 ± 7.21	31.44 ± 8.01	0.123	0.902
3 mo after treatment	47.58 ± 7.22a	39.03 ± 8.12a	4.977	0.000
Mental health
Before treatment	40.34 ± 6.31	39.45 ± 7.08	0.594	0.555
3 mo after treatment	66.16 ± 8.11a	50.91 ± 9.03a	7.947	0.000

^aP < 0.05 vs before treatment.

Table 6 Comparison of adverse event between the two groups, n (%)

Group	Number of cases	III-IV grade leukopenia	III-IV grade nausea and vomiting	III-IV grade diarrhea	III-IV grade mouth ulcer	III-IV grade abnormal liver and kidney function	III-IV grade thrombocytopenia
Observation group	40	8 (20.00)	11 (27.50)	13 (32.50)	9 (22.50)	15 (38.50)	10 (25.00)
Control group	40	5 (12.50)	7 (17.50)	4 (10.00)	8 (20.00)	12 (30.00)	3 (7.50)
t/χ2 value		0.827	1.147	6.050	0.075	0.503	4.501
P value		0.363	0.284	0.014	0.785	0.478	0.034